Abstract
ObjectiveThe aim of this study was to assess CD95 expression on peripheral blood lymphocytes in patients with chronic hepatitis C virus (HCV) infection, both under interferon treatment and without interferon treatment, in comparison with a control group to assess its role in the pathogenesis of chronic hepatitis C disease.BackgroundEgypt has the highest prevalence of HCV in the world, estimated nationally at 14.7%. Fas (APO-1/CD95)-mediated apoptosis plays an important role in liver cell destruction in viral hepatitis.Participants and methodsPeripheral blood lymphocytes were isolated from 15 patients with chronic HCV under interferon treatment and from 20 patients with HCV without interferon treatment, and CD95 expression was analyzed by flow cytometry. The results were compared with those of normal control volunteers.ResultsThe percentage of CD95 expression was significantly higher in patients with HCV without interferon treatment and in patients with HCV under interferon treatment compared with normal controls (27.09 ± 12.89 vs. 22.33 ± 11.42 vs. 11.09 ± 5.96, respectively). The percentage of CD95 expression did not differ significantly between patients with HCV without interferon treatment and patients with HCV under interferon treatment.ConclusionThe increase in CD95 expression on PBMCs among HCV patients supports its role in the pathogenesis of chronic hepatitis C disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
